NCT00167973

Brief Summary

This is an open-label multi-center Registry in patients with hemophilia B receiving BeneFIX. All patients who begin treatment with BeneFIX in European Union countries, will be eligible for participation. Patient demographics will be collected at baseline for all patients. A baseline FIX activity and Bethesda assay for inhibitor based on historical data should be recorded if available. Adverse events as defined in the protocol will also be reported on the appropriate forms. Data will be collected from patients on an ongoing basis to ensure that information is being captured for each patient being treated with BeneFIX.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
218

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2002

Longer than P75 for all trials

Geographic Reach
10 countries

90 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2002

Completed
3.7 years until next milestone

First Submitted

Initial submission to the registry

September 11, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 14, 2005

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2009

Completed
Last Updated

May 26, 2010

Status Verified

May 1, 2010

Enrollment Period

7.4 years

First QC Date

September 11, 2005

Last Update Submit

May 25, 2010

Conditions

Keywords

Hemophilia B

Outcome Measures

Primary Outcomes (1)

  • Observation for safety

    Study Duration

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All EU patients beginning treatment with BeneFIX

You may qualify if:

  • Patients with Hemophilia B scheduled to begin treatment with BeneFIX are eligible for Registry enrollment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (90)

Unknown Facility

Vienna, 1090, Austria

Location

Unknown Facility

Brussels, 1020, Belgium

Location

Unknown Facility

Brussels, 1090, Belgium

Location

Unknown Facility

Brussels, 1200, Belgium

Location

Unknown Facility

Edegem, 2650, Belgium

Location

Unknown Facility

Leuven, 3000, Belgium

Location

Unknown Facility

Montegnée, 4420, Belgium

Location

Unknown Facility

Amiens, 80 80054, France

Location

Unknown Facility

Angers, 49 49033, France

Location

Unknown Facility

Caen, 14 14033, France

Location

Unknown Facility

Chambéry, 73 73011, France

Location

Unknown Facility

Grenoble, 38 38043, France

Location

Unknown Facility

Le Chesnay, 78 78153, France

Location

Unknown Facility

Le Kremlin-Bicêtre, 94 94279, France

Location

Unknown Facility

Liffré, 35 35340, France

Location

Unknown Facility

Limoges, 87 87042, France

Location

Unknown Facility

Lyon, 03 69437, France

Location

Unknown Facility

Lyon, 69 69000, France

Location

Unknown Facility

Marseille, 13 13385, France

Location

Unknown Facility

Montmorency, 95 95160, France

Location

Unknown Facility

Montpellier, 34 34059, France

Location

Unknown Facility

Montpellier, 34 34295, France

Location

Unknown Facility

Nantes, 44 44093, France

Location

Unknown Facility

Nevers, 58 58020, France

Location

Unknown Facility

Nice, 06 06202, France

Location

Unknown Facility

Osséja, 66 66344, France

Location

Unknown Facility

Paris, 75 75674, France

Location

Unknown Facility

Paris, 75 75743, France

Location

Unknown Facility

Rouen, 76 76031, France

Location

Unknown Facility

Saint-Priest-en-Jarez, 42 42270, France

Location

Unknown Facility

Tours, 37 37044, France

Location

Unknown Facility

Erlangen, Bavaria, 91054, Germany

Location

Unknown Facility

Hamburg, Hamburg, 20246, Germany

Location

Unknown Facility

Münster, North Rhine-Westphalia, 48143, Germany

Location

Unknown Facility

Ancona, AN, 60100, Italy

Location

Unknown Facility

Bari, BA, 70124, Italy

Location

Unknown Facility

Catania, CT, 95124, Italy

Location

Unknown Facility

Catanzaro, CZ, 88100, Italy

Location

Unknown Facility

Milan, MI, 20162, Italy

Location

Unknown Facility

Palermo, PA, 90134, Italy

Location

Unknown Facility

Pescara, PE, 65100, Italy

Location

Unknown Facility

Parma, PR, 43100, Italy

Location

Unknown Facility

Reggio Calabria, RC, 89100, Italy

Location

Unknown Facility

Sassari, SS, 07100, Italy

Location

Unknown Facility

Napoli, 80131, Italy

Location

Unknown Facility

Padua, Italy

Location

Unknown Facility

Palermo, 90100, Italy

Location

Unknown Facility

Perugia, 06126, Italy

Location

Unknown Facility

Roma, 00161, Italy

Location

Unknown Facility

Vicenza, 36100, Italy

Location

Unknown Facility

Amsterdam, 1007 MB, Netherlands

Location

Unknown Facility

Breda, 4818 CK, Netherlands

Location

Unknown Facility

Eindhoven, 5623 EJ, Netherlands

Location

Unknown Facility

Maastricht, 6229 HX, Netherlands

Location

Unknown Facility

Nijmegen, 6525 GA, Netherlands

Location

Unknown Facility

Utrecht, 3584 CX, Netherlands

Location

Unknown Facility

Coimbra, 3000, Portugal

Location

Unknown Facility

Almería, 04009, Spain

Location

Unknown Facility

Barcelona, 08035, Spain

Location

Unknown Facility

Burgos, 09005, Spain

Location

Unknown Facility

Cadiz, 11009, Spain

Location

Unknown Facility

Esplugues de Llobregat, 08950, Spain

Location

Unknown Facility

Madrid, 28046, Spain

Location

Unknown Facility

Mérida-Badajoz, 06800, Spain

Location

Unknown Facility

Santander, 38003, Spain

Location

Unknown Facility

Seville, 41013, Spain

Location

Unknown Facility

Valencia, 46009, Spain

Location

Unknown Facility

Valladolid, 47010, Spain

Location

Unknown Facility

Vitoria-Gasteiz, 01004, Spain

Location

Unknown Facility

Zaragoza, 50009, Spain

Location

Unknown Facility

Malmo, 205 02, Sweden

Location

Unknown Facility

Stockholm, 171 76, Sweden

Location

Unknown Facility

Truro, Cnwll, TR1 3LJ, United Kingdom

Location

Unknown Facility

London, Gt Lon, SE13 6LH, United Kingdom

Location

Unknown Facility

London, Gt Lon, W12 0HS, United Kingdom

Location

Unknown Facility

London, Gt Lon, WC1N 3JH, United Kingdom

Location

Unknown Facility

Manchester, Gt Man, M27 4HA, United Kingdom

Location

Unknown Facility

Edinburgh, Loth, EH16 4SA, United Kingdom

Location

Unknown Facility

Liverpool, Mersyd, L12 2AP, United Kingdom

Location

Unknown Facility

Sheffield, Mersyd, L12 2AP, United Kingdom

Location

Unknown Facility

Oxford, Oxon, OX3 L7J, United Kingdom

Location

Unknown Facility

Sheffield, Syorks, S10 2TH, United Kingdom

Location

Unknown Facility

Cardiff, W Glam, CF4 4XW, United Kingdom

Location

Unknown Facility

Birmingham, Wstmid, B4 6NL, United Kingdom

Location

Unknown Facility

Wolverhampton, Wstmid, WV10 0QP, United Kingdom

Location

Unknown Facility

Leeds, Wyorks, L59 7FF, United Kingdom

Location

Unknown Facility

London, E1 1BB, United Kingdom

Location

Unknown Facility

Plymouth, United Kingdom

Location

Unknown Facility

Poole, BH15 2JB, United Kingdom

Location

Unknown Facility

Sheffield, S10 2JF, United Kingdom

Location

Related Publications (1)

  • Rendo P, Smith L, Lee HY, Shafer F. Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities. Blood Coagul Fibrinolysis. 2015 Dec;26(8):912-8. doi: 10.1097/MBC.0000000000000359.

MeSH Terms

Conditions

Hemophilia B

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, InheritedBlood Coagulation DisordersHematologic DiseasesHemic and Lymphatic DiseasesCoagulation Protein DisordersHemorrhagic DisordersGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGenetic Diseases, X-Linked

Study Officials

  • Medical Monitor

    Wyeth is now a wholly owned subsidiary of Pfizer

    STUDY DIRECTOR
  • Trial mANAGER

    For Germany, MedInfoDEU@wyeth.com

    PRINCIPAL INVESTIGATOR
  • Trial Manager

    For Italy, descresg@wyeth.com

    PRINCIPAL INVESTIGATOR
  • Trial Manager

    For Belgium, trials-BEL@wyeth.com

    PRINCIPAL INVESTIGATOR
  • Trial Manager

    For Netherlands, trials-NL@wyeth.com

    PRINCIPAL INVESTIGATOR
  • Trial Manager

    For Sweden, MedInfoNord@wyeth.com

    PRINCIPAL INVESTIGATOR
  • Trial Manager

    For Austria, WPVIMED@wyeth.com

    PRINCIPAL INVESTIGATOR
  • Trial Manager

    For UK, ukmedinfo@wyeth.com

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 11, 2005

First Posted

September 14, 2005

Study Start

January 1, 2002

Primary Completion

June 1, 2009

Study Completion

June 1, 2009

Last Updated

May 26, 2010

Record last verified: 2010-05

Locations